Estimates Revisions Scribe Therapeutics Inc.
Stocks
SCTX
US8110331092
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
16:00:00 2026-08-27 EDT
|
5-day change | 1st Jan Change | ||
| 28.84 USD | -9.02% |
|
-12.15% | - |
| 08-24 | Top Premarket Gainers | MT |
| 08-18 | Guggenheim Initiates Scribe Therapeutics at Buy With $50 Price Target | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| - | |||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Cash or Net Debt
- Stock Market
- Stocks
- SCTX Stock
- Consensus Scribe Therapeutics Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
